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In December 2019, the outbreak of pneumonia caused by the novel coronavirus (SARS-CoV-2) emerged in China, 
representing a serious threat to public health and thus attracting worldwide attention. Recent studies revealed 
that the blockage of small airways by mucus plugs is considered to be an important pathophysiological change 
in COVID-19 patients. To date, no definite and effective treatments have been presented for COVID-19. Vitamin 
C is widely available and has shown the potential to inhibit airway mucus secretion, but its effect on improving 
the outcome of COVID-19 patients is unclear. 
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Introduction 
In December 2019, the outbreak of pneumonia caused by 
the novel coronavirus (SARS-CoV-2) emerged in China, and 
the resulting disease was subsequently named COVID-19[1, 2]. 
It presented a serious public health threat. On March 10, 2020, 
more than 5000 deaths caused by COVID-19 were reported 
around the world in more than 100 countries. The symptoms 
of COVID-19 may include fever, cough, general breathing 
difficulties, organ failure or even death, posing a severe threat 
to society as a whole. At present, no effective antiviral 
treatment or vaccine is available for COVID-19. Several 
studies have assessed the efficacy and safety of drugs such as 
lopinavir/ritonavir and remdesivir in patients with COVID-
19[3, 4]. Chloroquine is currently a possible therapeutic option 
for COVID-19[5]. 
Recently, the pathological findings of COVID-19, which 
are partially similar to those of SARS, were found to include 
bilateral diffuse alveolar damage with cellular fibromyxoid 
exudates, and small airway obstruction caused by sputum 
thrombus was also observed in the lungs of COVID-19 
patients[6]. Furthermore, SARS-CoV was demonstrated to 
depend on activation of the oxidative stress machinery. Based 
on these results, anti-mucus medications and antioxidants 
may be effective for the treatment of COVID-19. Vitamin C, 
a natural antioxidant, is widely available and has shown the 
potential to inhibit mucus secretion, but its effect on 
improving the outcome of COVID-19 patients is unclear.  
CASE REPORT 
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Figure 1. Laboratory results show lymphopenia (780 cells/μl), serum C-reactive protein (CRP), and Interleukin-6 (IL-6) are normal. 
 
Case Report 
A 64-year-old woman living in Guizhou, China, was 
exposed to SARS-CoV-2 (severe acute respiratory syndrome 
coronavirus 2) through close contact with confirmed COVID-
19 patients. The initial symptoms, including cough and 
muscle pain, were observed on February 12. She was admitted 
and isolated in a negative pressure room on the same day. She 
was confirmed to have COVID-19 by viral nucleic acid 
detection from a throat swab using real-time polymerase 
chain reaction (RT-PCR). Apart from a history of diabetes 
with irregular medical follow-up, she had no other underlying 
diseases before the onset of COVID-19. 
After admission, the laboratory results showed 
lymphopenia (780 cells/μl), and the serum C-reactive protein 
(CRP) and interleukin-6 (IL-6) levels were normal (Figure 1). 
No evidence of abnormalities of liver function, renal function, 
myocardial enzymes, electrolytes or serum procalcitonin was 
found. High-resolution computed tomography (HRCT) was 
performed at the onset of the disease, and the results revealed 
that ground glass opacities (GGO) were the main radiological 
finding (Figure 2A) and were distributed subpleurally in the 
lower lobes bilaterally. The treatments administered after 
admission included antiviral therapy with interferon alpha-2β 
(5 million units twice daily via atomization inhalation) and 
lopinavir/ritonavir (500 mg twice daily orally). On day 10 of 
the illness, the muscle pain disappeared, and cough was 
relieved, but the symptoms of shortness of breath and yellow, 
sticky phlegm appeared (Figure 3A). The nucleic acid test 
was still positive, and the lymphopenia worsened (480 
cells/μl). Moreover, the levels of serum CRP and IL-6 
increased significantly (Figure 1). The supplementation of 
oxygen with a nasal cannula (3 L/min) could not improve the 
patient’s symptom of breathing difficulty, and arterial blood 
gas analysis indicated respiratory failure with an arterial 
oxygen tension (PaO2) of 55 mmHg and an oxygenation 
index (OI) of 167 mmHg. Following therapy with oxygen via 
a high-flow nasal cannula (HFNC) (concentration 80%, flow 
rate 65 L/min), the SPO2 reached 93%. The HRCT 
examination indicated that the lesions showed a bilateral 
multilobe distribution with diffuse GGO and a crazy-paving 
pattern (Figure 2B). Considering the failure to control 
coinfection of SARS-CoV-2 and bacteria, lopinavir/ritonavir 
were replaced by chloroquine, and piperacillin/tazobactam, 
ambroxol hydrochloride and N-acetylcysteine were added to 
the treatment regimen. 
After receiving medication, the serum CRP and IL-6 levels 
were decreased, and the lymphocyte count (960 cells/μl) 
returned to normal levels. The HRCT imaging indicated that 
the GGO were obviously absorbed without any crazy-paving 
pattern (Figure 2C). However, the patient still had the 
symptoms of shortness of breath and yellow sticky sputum 
(Figure 3B). Moreover, the OI was significantly decreased 
even though the flow rate and oxygen concentration of the  
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Figure 2. A high-resolution computed tomography (HRCT) revealed that ground glass opacities (GGO) was the main 
radiological demonstration distributed subpleurally in the lower lobes bilaterally. 
 
Figure 3. Yellow sticky phlegm. 
 
 
HFNC-administered oxygen were slightly reduced. 
Subsequently, high doses of vitamin C were strategically used 
(3 g was given intravenously tid) for 8 days. Subsequently, 
the symptoms and signs of the patient, including breathing 
difficulties and yellow sputum, gradually improved. The OI 
increased from 152 mmHg to 244 mmHg as the flow rate of 
the HFNC oxygen therapy was gradually reduced from 65 
L/min to 30 L/min, and the oxygen concentration was reduced 
from 80% to 30%. Fortunately, on day 21 of the illness, the 
oxygen supplementation via HFNC was switched to nasal 
administration (FIO2 33%). Finally, the arterial blood gas 
analysis on exposure to the open air was as follows: PO2 76.4 
mmHg and OI＞300 mmHg. Moreover, the result of the 
detection of SARS-CoV-2 by the RT-PCR assay was negative, 
and the CT examination indicated that the lesion was 
gradually being absorbed, and pulmonary fibrosis and the 
crazy-paving pattern had disappeared. On day 23 of the illness, 
the patient was discharged, and it was suggested that she 
quarantine at home for at least 14 days. 
Discussion 
The outbreak of COVID-19 triggered a global public health 
emergency, and although the serious symptoms and signs of 
pulmonary disease have caused clinicians and researchers to 
be concerned, there are still no effective treatments.  
The patient showed typical signs and symptoms of cough, 
yellow sticky phlegm and breathing difficulty after infection 
with SARS-CoV-2. Additionally, consistent with the current 
pathological report, the chest CT examination images 
revealed multiple patchy ground glass opacities in the 
bilateral subpleural areas. According to the WHO[7], the 
management of COVID-19 has mainly focused on case 
detection, infection prevention, and supportive care. However, 
no specific antiviral drug is recommended for treatment 
because of a lack of evidence. After admission to the hospital, 
the antiviral treatments lopinavir/ritonavir and alpha-2β were 
given to the patient, but the improvement of the illness in 
response was limited. The Lymp remained decreased, 
indicating the activity of SARS-COV-2. Studies have 
indicated that serious and sustained Lymp decreases are 
associated with disease severity and mortality[8], and the 
Lymp results and patient pulmonary symptoms and CT 
images confirmed the progression of the illness.   
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Chloroquine is used to prevent and treat malaria and is 
efficacious as an anti-inflammatory agent for the treatment of 
rheumatoid arthritis and lupus erythematosus. Recent 
publications have paid more attention to the potential of 
chloroquine for the treatment of COVID-19 patients and 
found that it plays an important role in inhibiting the 
exacerbation of COVID-19 pneumonia, improving lung 
imaging findings, and promoting a negative viral conversion 
[5, 9]. However, the symptoms and signs of pulmonary disease 
in this case were not improved by the use of chloroquine.  
The imbalance between oxidation and antioxidants leads to 
multisystemic inflammation, and the evidence indicates that 
oxidative stress plays a pathogenic role in inflammatory 
diseases [10]. During this process, nonenzymatic antioxidants 
such as vitamin C protect against oxidative stress. When the 
levels of inflammatory indicators such as CRP and IL-6 
increase and hypoxemia or respiratory failure worsens, 
empirical use of antibiotics to prevent secondary infection and 
the use of HFNC oxygen therapy are essential to reduce 
mortality. Unfortunately, although antibacterial and 
apophlegmatic drugs were also used, respiratory failure still 
persisted. Recently, the pathological findings included 
bilateral diffuse alveolar damage with cellular fibromyxoid 
exudates in patients with COVID-19[6]. Therefore, worsening 
of hypoxemia or respiratory failure might be associated with 
small airway obstruction caused by sputum thrombus. Based 
on these theories, antimucus medications and antioxidants 
might be effective in resolving these problems. In this case, 
conventional expectorants, such as ambroxol hydrochloride 
and N-acetylcysteine, failed to improve the patient’s 
pulmonary function. Vitamin C is the principal dietary 
antioxidant that protects erythrocytes from damage caused by 
reactive oxygen species[11] and was found to be effective in 
inhibiting mucus secretion. Therefore, high doses of vitamin 
C were used in this case to improve the symptoms. In line with 
our expectations, 3 days after the use of vitamin C, the clinical 
observations, laboratory data and CT results indicated that 
vitamin C significantly improved the clinical symptoms and 
successfully enhanced the OI. Although the exact mechanism 
of the improvement of the illness by vitamin C is unclear, it 
could be a reasonable guess that high doses of vitamin C can 
improve small airway mucus obstruction to relieve respiratory 
failure. 
Our clinical findings provide new insights into the 
treatment of COVID-19 pneumonia, which might help 
physicians implement a timely therapeutic strategy for similar 
severe patients and increase the cure rate. Considering its low 
toxicity and easy availability, vitamin C could be 
recommended to relatively high-risk groups of patients with 
COVID-19 pneumonia. However, more evidence is needed to 
prove the clinical efficacy of high doses of vitamin C and to 
draw definitive conclusions based on well-controlled clinical 
trials. 
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